

**ASX ANNOUNCEMENT**

**\$2 MILLION CAPITAL RAISING**

**SYDNEY, Wednesday 11 December 2013: Cellmid Limited (ASX: CDY)** (the Company), is pleased to advise that it has successfully completed the placement of 66,666,666 fully paid ordinary shares at an issue price of 3 cents per share (\$0.03) (Placement), raising a total of \$2,000,000 before costs.

The issue price for the Placement shares is at a discount of 14.2% to the 10 day volume weighted average price of the Company's shares immediately prior to the Placement offer.

Placement offers were made to sophisticated or professional investors pursuant to section 708 of the Corporations Act. Shares accepted under the Placement are expected to be issued on 20 December 2013. The shares will have the same terms as and rank pari passu with existing ordinary shares.

The Company will use the money raised to fund the commencement of investigational new drug (IND) enabling studies and in preparation for its therapeutic antibody program to become clinical trial ready.

The Company will not seek shareholder approval for the issue of shares under the Placement.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced development programs involve using its anti-midkine antibodies for the treatment of cancer and inflammatory diseases. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. For further information please see [www.cellmid.com.au](http://www.cellmid.com.au).